Endometrial ultrasound features associated with methotrexate success in tubal ectopic pregnancy: a prospective case series.
Endometrial ultrasound features such as thickness and echo pattern may provide additional insights into the likelihood of methotrexate success in ectopic pregnancies, but further analysis is needed to confirm their independent predictive value.
Where it sits
this study against the rest of the hcg (human chorionic gonadotropin) corpusSummary and findings
This study measured the association between endometrial ultrasound features and treatment success in women with tubal ectopic pregnancy receiving a single dose of methotrexate. A total of 177 women were included, and treatment success was defined as a ≥15% decline in serum β-hCG from day 4 to day 7 post-treatment. The study found that treatment success occurred in 53.1% of participants.
Abstract
<h4>Background</h4>Ectopic pregnancy is an important cause of maternal morbidity in early pregnancy. Single-dose methotrexate is commonly used for haemodynamically stable women with unruptured tubal ectopic pregnancy, but treatment success varies. The association between pre-treatment endometrial ultrasonographic features and treatment outcome remains uncertain.<h4>Methods</h4>This prospective case series included 177 women with confirmed tubal ectopic pregnancy who received a single intramuscular dose of methotrexate (50 mg/m<sup>2</sup>) at two tertiary hospitals in Isfahan, Iran, between January and December 2024. Transvaginal ultrasonography was used to measure endometrial thickness and classify the endometrial echo pattern as homogeneous or triple-layer. Treatment success was defined as a ≥ 15% decline in serum β-hCG from day 4 to day 7 after treatment, followed by weekly monitoring until the concentration became undetectable. Associations with treatment success were assessed using univariable logistic regression.<h4>Results</h4>Treatment success occurred in 94 of 177 women (53.1%). Responders had lower median baseline β-hCG concentrations (500 versus 1400 mIU/mL; <i>P</i> < 0.001), thinner endometrium (7 versus 9 mm; <i>P</i> = 0.009), and a higher proportion of homogeneous endometrial appearance (65.9 versus 49.4%; <i>P</i> = 0.026). In univariable logistic regression, baseline β-hCG (<i>P</i> = 0.003), ectopic pregnancy size (<i>P</i> = 0.013), and homogeneous endometrial appearance (<i>P</i> = 0.027) were significantly associated with treatment success; endometrial thickness showed borderline evidence of association (<i>P</i> = 0.0498).<h4>Conclusion</h4>Baseline β-hCG, ectopic pregnancy size, and endometrial appearance were associated with single-dose methotrexate success in univariable analyses, while endometrial thickness showed a borderline association. Because no multivariable model was fitted, these findings should not be interpreted as independent predictors. Endometrial ultrasonographic features may provide supportive information alongside established clinical factors such as baseline β-hCG.
Background
Not reported in abstract.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Not reported in abstract.
Limitations
Not reported in abstract.